Inca identifies bonanza grade silver at Riqueza


Published 04-JUL-2019 14:28 P.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Inca Minerals Ltd (ASX:ICG) has received assay results from 22 rock chip channel samples collected during a brief reconnaissance program that was conducted at Riqueza in conjunction with a more detailed expert porphyry/skarn mapping program.

Both programs are part of the Inca-South32 Year-1 exploration campaign.

The assay results as detailed below indicate strong epithermal silver-copper-manganese mineralisation broadly associated with a rhyolite dome and related structures, recently interpreted at Alteration Ridge.

Inca has found Bonanza grade silver.

Notably, bonanza grade silver and strong copper mineralisation was identified at the Cuncayoc Copper Prospect.

These included channel length samples grading 919 g/t silver and 2.7% copper.

Further promising grades stemmed from the identification of a mineralised structure at the Colina Roja Prospect, including silver grading 68 g/t and copper grading 1.4%.

This strong epithermal mineralisation corresponds to several priority one geophysical targets as highlighted below.

A detailed grid soil geochemical program has been launched.

While these highly promising assay results are, at this time, from a small number of samples the company is so encouraged by the data that management has launched a very detailed grid soil geochemical program to cover these same areas, and follow-up rock chip sampling is planned at Cuncayoc Copper.

Strong start to extensive exploration program

These are impressive results given that they come at a very early stage of what is a substantial exploration program being conducted by Inca and South32 (ASX:S32)

A near project-wide grid soil geochemistry program commenced at Riqueza in late May 2019.

As at 1 July, 2019, a total of 125 soil samples had been taken out of a program total of 1,269 samples.

Soil samples are being taken on a 200 metre by 200 metre North-South/East-West grid and will be subject to multi-element analysis.

The objective of the soil program is to identify geochemical indictors of (pathways to) hidden, or buried, porphyry and/or skarn mineralisation.

Of particular interest are the large expanses of non-outcrop within the greater Alteration Ridge Area where the usefulness of mapping is limited.

It is expected that the geochemical sampling will be especially useful in identifying any potential anomalies in these areas.

Detailed localised geological mapping and reconnaissance rock chip channel sampling will continue as a parallel program to the soil program so that any/all zones of mineralisation, important structures and alteration zones found during soil sampling are described and sampled in a timely manner.

The WorldView3 satellite data has now been provided to geophysics/remote sensing specialists Resource Potentials for detailed analysis.

The results of this work are anticipated in July 2019, and these will provide additional layers of data that will further assist in project-wide target generation, refinement and prioritisation.

Consequently, there could be further share price catalysts emerge as July unfolds.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free